Opportunity Radar

← Back to search

Grant

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
G
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
RFA-HL-26-018
Posted
Nov 22, 2024
Response due
Dec 23, 2027
Archive date
Jan 28, 2028
CFDA / Assistance listing
93.233,93.837,93.838,93.839,93.855
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

Similar open opportunities